Efficacy, Safety and Pharmacokinetics of BIRB 796 BS Tablets in Patients With Active Rheumatoid Arthritis
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to determine the efficacy (including American College of Rheumatology (ACR) 20 response
rate), safety, and pharmacokinetics of BIRB 796 BS as monotherapy in patients with moderate
to severe rheumatoid arthritis who have failed at least one disease modifying antirheumatic
drug (DMARD)